India, March 5 -- image credit- shutterstock

US-based Parse Biosciences, the leader in accessible and scalable single cell sequencing, has affirmed plans to proceed with development and future release of their Evercode single cell chromatin products. This comes on the heels of Parse invalidating the patents that 10x Genomics had asserted against Parse's Evercode Whole Transcriptome products and the subsequent cancellation of a trial on those patents.

In connection with these events, Parse reached a favorable resolution with 10x Genomics over other patents that are unrelated to either Parse's existing Evercode products or its forthcoming chromatin accessibility products.

Parse's chromatin accessibility technology leverages a novel appro...